Would you use the MIPSS-PV risk scoring to decide in decision making for cytoreductive therapy in PV?

If so, would you do bone marrow biopsy or send for NGS panel in blood to look for high risk mutations? NCCN lists this as the risk criteria.

Answer from: Medical Oncologist at Community Practice

I think the MIPSS-PV is helpful in understanding predicted overall survival and appreciating the risk of progression, the decision to cytoreduce is still routed in the classic thrombosis risk model of age plus thrombosis history. I would certainly recommend getting an NGS panel to better understand...

Comments

Medical Oncologist at Massachusetts General Hospital
I agree completely with Dr. @Gerds. The MIPSS-PV s...

Medical Oncologist at Taussig Cancer Institute
I agree that we need better (or at least updated a...

Please select the option that best describes you:

Would you use the MIPSS-PV risk scoring to decide in decision making for cytoreductive therapy in PV?

Related Questions